S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: World shares are mixed after a tech-led retreat on Wall Street
Closing prices for crude oil, gold and other commodities
Predicting a Bear Market: 7 Signs and Why it's Tough to Do
United Airlines Soars on Earnings Beat
CSX profit drops 10% despite railroad delivering 3% more freight in first quarter
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: World shares are mixed after a tech-led retreat on Wall Street
Closing prices for crude oil, gold and other commodities
Predicting a Bear Market: 7 Signs and Why it's Tough to Do
United Airlines Soars on Earnings Beat
CSX profit drops 10% despite railroad delivering 3% more freight in first quarter
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: World shares are mixed after a tech-led retreat on Wall Street
Closing prices for crude oil, gold and other commodities
Predicting a Bear Market: 7 Signs and Why it's Tough to Do
United Airlines Soars on Earnings Beat
CSX profit drops 10% despite railroad delivering 3% more freight in first quarter
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Abbott Laboratories Outlook is Healthy: Buy the Dip
Stock market today: World shares are mixed after a tech-led retreat on Wall Street
Closing prices for crude oil, gold and other commodities
Predicting a Bear Market: 7 Signs and Why it's Tough to Do
United Airlines Soars on Earnings Beat
CSX profit drops 10% despite railroad delivering 3% more freight in first quarter

Akero Therapeutics (AKRO) SEC Filings & 10K Form

$21.60
-0.19 (-0.87%)
(As of 04/17/2024 ET)

Recent Akero Therapeutics SEC Filings

DateFilerForm TypeView
04/16/2024
3:30 PM
Akero Therapeutics (Filer)
Form PRE 14A
04/03/2024
5:55 PM
Akero Therapeutics (Issuer)
Young Jonathan (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
04/01/2024
3:17 PM
Akero Therapeutics (Subject)
Young Jonathan (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/18/2024
3:31 PM
Akero Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/15/2024
3:42 PM
Akero Therapeutics (Issuer)
Rolph Timothy (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/15/2024
3:42 PM
Akero Therapeutics (Issuer)
Young Jonathan (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/15/2024
3:43 PM
Akero Therapeutics (Issuer)
Cheng Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/15/2024
3:44 PM
Akero Therapeutics (Issuer)
White William Richard (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/15/2024
3:45 PM
Akero Therapeutics (Issuer)
Yale Catriona (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/15/2024
9:08 AM
Akero Therapeutics (Subject)
GENERAL ATLANTIC, L.P. (Filed by)
Form SC 13G
03/06/2024
7:13 PM
Akero Therapeutics (Issuer)
Yale Catriona (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/06/2024
7:14 PM
Akero Therapeutics (Issuer)
Cheng Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/06/2024
4:25 PM
Akero Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/06/2024
4:16 PM
Akero Therapeutics (Filer)
Form 424B5
03/05/2024
4:16 PM
Akero Therapeutics (Issuer)
Young Jonathan (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/04/2024
4:30 PM
Akero Therapeutics (Subject)
Cheng Andrew (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/04/2024
6:55 AM
Akero Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/29/2024
3:42 PM
Akero Therapeutics (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
02/29/2024
6:30 AM
Akero Therapeutics (Filer)
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
02/29/2024
6:15 AM
Akero Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/14/2024
1:19 PM
Akero Therapeutics (Subject)
PFIZER INC (Filed by)
Form SC 13G/A
02/14/2024
6:06 AM
Akero Therapeutics (Subject)
RTW INVESTMENTS, LP (Filed by)
Form SC 13G
02/13/2024
8:40 PM
Akero Therapeutics (Subject)
Avidity Partners Management LP (Filed by)
Form SC 13G/A
02/13/2024
5:30 PM
Akero Therapeutics (Subject)
ALKEON CAPITAL MANAGEMENT LLC (Filed by)
Form SC 13G/A
02/13/2024
10:31 AM
Akero Therapeutics (Subject)
JANUS HENDERSON GROUP PLC (Filed by)
Form SC 13G/A
02/07/2024
6:23 AM
ADAGE CAPITAL PARTNERS GP, L.L.C. (Filed by)
Akero Therapeutics (Subject)
Form SC 13G/A
01/25/2024
8:36 AM
Akero Therapeutics (Subject)
STATE STREET CORP (Filed by)
Form SC 13G/A
12/29/2023
7:30 PM
Akero Therapeutics (Issuer)
Young Jonathan (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/29/2023
5:07 PM
Akero Therapeutics (Subject)
Young Jonathan (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/18/2023
7:49 PM
Akero Therapeutics (Issuer)
Yale Catriona (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/18/2023
7:37 PM
Akero Therapeutics (Issuer)
Cheng Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/18/2023
7:39 PM
Akero Therapeutics (Issuer)
Young Jonathan (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/18/2023
7:40 PM
Akero Therapeutics (Issuer)
White William Richard (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/18/2023
7:29 PM
Akero Therapeutics (Issuer)
Rolph Timothy (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/18/2023
6:08 AM
Akero Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/12/2023
3:43 PM
Akero Therapeutics (Issuer)
Young Jonathan (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/12/2023
3:43 PM
Akero Therapeutics (Issuer)
White William Richard (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/12/2023
3:35 PM
Akero Therapeutics (Issuer)
Lamy Patrick (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/12/2023
3:38 PM
Akero Therapeutics (Issuer)
Rolph Timothy (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/12/2023
3:26 PM
Akero Therapeutics (Issuer)
Yale Catriona (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/11/2023
7:59 PM
Akero Therapeutics (Issuer)
Cheng Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
The “Perfect Storm” for Gold (Ad)

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!
12/11/2023
8:06 PM
Akero Therapeutics (Issuer)
Graham G. Walmsley (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/05/2023
7:37 AM
Akero Therapeutics (Issuer)
Graham G. Walmsley (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/21/2023
4:30 PM
Akero Therapeutics (Issuer)
Young Jonathan (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/13/2023
4:37 PM
Akero Therapeutics (Issuer)
White William Richard (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/13/2023
6:33 AM
Akero Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
11/13/2023
6:15 AM
Akero Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/10/2023
7:04 AM
Akero Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/04/2023
7:33 PM
Akero Therapeutics (Issuer)
Young Jonathan (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/04/2023
7:41 PM
Akero Therapeutics (Issuer)
Cheng Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/02/2023
5:17 PM
Akero Therapeutics (Subject)
Young Jonathan (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/02/2023
5:21 PM
Akero Therapeutics (Subject)
Cheng Andrew (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/25/2023
7:28 PM
Akero Therapeutics (Issuer)
Young Jonathan (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/25/2023
7:30 PM
Akero Therapeutics (Issuer)
Rolph Timothy (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/25/2023
7:31 PM
Akero Therapeutics (Issuer)
Yale Catriona (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/25/2023
7:31 PM
Akero Therapeutics (Issuer)
White William Richard (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/25/2023
7:36 PM
Akero Therapeutics (Issuer)
Cheng Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/18/2023
5:48 PM
Akero Therapeutics (Issuer)
Cheng Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/30/2023
6:04 PM
Akero Therapeutics (Issuer)
Yale Catriona (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/30/2023
6:04 PM
Akero Therapeutics (Issuer)
Cheng Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/10/2023
8:02 PM
Akero Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
08/11/2023
5:09 AM
Akero Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/03/2023
3:13 PM
Akero Therapeutics (Issuer)
Cheng Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/01/2023
6:52 PM
Akero Therapeutics (Issuer)
Graham G. Walmsley (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/06/2023
7:44 PM
Akero Therapeutics (Issuer)
Cheng Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/03/2023
12:07 PM
Akero Therapeutics (Subject)
Cheng Andrew (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/27/2023
6:12 PM
Akero Therapeutics (Issuer)
Cheng Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/27/2023
5:00 PM
Akero Therapeutics (Issuer)
Xu Yuan (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/27/2023
4:52 PM
Akero Therapeutics (Issuer)
Heyman Tomas J. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/27/2023
4:55 PM
Akero Therapeutics (Issuer)
Henderson Jane (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/27/2023
4:58 PM
Akero Therapeutics (Issuer)
Judy Chou (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/27/2023
4:39 PM
Akero Therapeutics (Issuer)
Iwicki Mark T (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/27/2023
4:48 PM
Akero Therapeutics (Issuer)
Harrison Seth Loring (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/27/2023
4:48 PM
Akero Therapeutics (Issuer)
Graham G. Walmsley (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/26/2023
4:29 PM
Akero Therapeutics (Subject)
Rolph Timothy (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/26/2023
3:02 PM
Akero Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/23/2023
7:06 PM
Akero Therapeutics (Issuer)
Yale Catriona (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/22/2023
4:20 PM
Akero Therapeutics (Issuer)
White William Richard (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/21/2023
4:54 PM
Akero Therapeutics (Issuer)
Heyman Tomas J. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/21/2023
4:46 PM
Akero Therapeutics (Issuer)
Rolph Timothy (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/21/2023
4:47 PM
Akero Therapeutics (Issuer)
Henderson Jane (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/16/2023
5:00 PM
Akero Therapeutics (Subject)
Heyman Tomas J. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/16/2023
4:41 PM
Akero Therapeutics (Subject)
Henderson Jane (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/16/2023
3:22 PM
Akero Therapeutics (Subject)
Rolph Timothy (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/15/2023
8:38 PM
Akero Therapeutics (Issuer)
Cheng Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/15/2023
8:41 PM
Akero Therapeutics (Issuer)
White William Richard (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/15/2023
8:29 PM
Akero Therapeutics (Issuer)
Yale Catriona (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/15/2023
8:35 PM
Akero Therapeutics (Issuer)
Young Jonathan (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/15/2023
8:35 PM
Akero Therapeutics (Issuer)
Rolph Timothy (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/15/2023
8:26 PM
Akero Therapeutics (Issuer)
Graham G. Walmsley (Reporting)
Form 4/A
06/05/2023
5:23 PM
Akero Therapeutics (Issuer)
Cheng Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
The “Perfect Storm” for Gold (Ad)

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!
06/05/2023
7:05 AM
Akero Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/23/2023
8:55 PM
Akero Therapeutics (Issuer)
Graham G. Walmsley (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/15/2023
6:30 AM
Akero Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
05/15/2023
6:19 AM
Akero Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/03/2023
7:28 PM
Akero Therapeutics (Issuer)
Cheng Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
(Data available from 1/1/2016 forward)


Related Companies and Tools

This page (NASDAQ:AKRO) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners